Colon adenocarcinoma multidrug resistance reverted by Euphorbia diterpenes: Structure-activity relationships and pharmacophore modeling

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1015-1024

  Reis, Mariana ^a   Ferreira, Ricardo J ^a   Serly, Julianna ^b   Duarte, Noélia ^a   Madureira, Ana M ^a   Santos, Daniel J V A ^a   Molnár, Joséph ^b   Ferreira, Maria José U ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Docking; Euphorbia; Euphorbiaceae; Jatrophane; Lathyrane; Macrocyclic diterpenes; Multidrug resistance; P glycoprotein; Pharmacophore

Indexed keywords

1 BETA,5 ALPHA,14 ALPHA,17 ALPHA TETRAACETOXY 3 BETA BENZOYLOXY 15 BETA HYDROXY 9 OXO PARALIANE; 1,5,14 TRIACETOXY 3 BENZOYLOXY SEGETALOL; 5 ACETOXY 3 BENZOYLOXY SEGETALOL; DITERPENE; DOXORUBICIN; EUPHOPORTLANDOL B; EUPHOPUBESCENE; EUPHOPUBESCENOL; LATI1AGASCENE B; LATI1AGASCENE D; LATI1AGASCENE H; LATI1AGASCENE I; MULTIDRUG RESISTANCE PROTEIN; PEPLUANIN D; PUBESCENE A; PUBESCENE C; PUBESCENE D; RHODAMINE 123; TUCKEYANOL A; TUCKEYANOL B; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CLUSTER ANALYSIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; EUPHORBIA; HUMAN; HUMAN CELL; MOLECULAR DOCKING; MULTIDRUG RESISTANCE; PHARMACOPHORE; PROTEIN EXPRESSION; STRUCTURE ACTIVITY RELATION;

ADENOCARCINOMA; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; COLONIC NEOPLASMS; DITERPENES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; EUPHORBIA; HUMANS; MOLECULAR DOCKING SIMULATION; P-GLYCOPROTEIN; STRUCTURE-ACTIVITY RELATIONSHIP; UP-REGULATION;

EID: 84872231481     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529655     Document Type: Article

References (35)

1. Perez-Tomas, R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem., 2006, 13, 1859-1876.
2. Szakács, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman, M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov., 2006, 5, 219-234.
3. Thomas, H.; Coley, H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting pglycoprotein. Cancer Control., 2003, 10, (2), 159-165.
4. Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System. Physiol. Rev., 2006, 86, 1179-1236.
5. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug Resistance in Cancer: Role of ATP-Dependent Transporters. Nat. Rev. Cancer., 2002, 2, 48-58.
6. Baumert, C.; Hilgeroth, A., Recent advances in the development of P-gp inhibitors. Anti Cancer Agents Med. Chem., 2009, 9, 415-436.
7. Ambudkar, S.V.; Kimchi-Sarfaty, C.; Sauna, Z.E.; Gottesman, M.M. P-glycoprotein: from genomics to mechanism. Oncogene, 2003, 22, 7468-7485.
8. Baguley, B.C. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol., 2010, 46, 308-316.
9. Stouch, T.R.; Gudmundsson, O. Progress in understanding the structure-activity relationships of P-glycoprotein. Adv. Drug. Deliv. Rev., 2002, 54, 315-328.
10. Klepsch, F.; Ecker, G.F. Impact of the recent Mouse PGlycoprotein Structure for Structure-Based Ligand Design. Mol. Inf., 2010, 29, 276-286.
11. Gutmann, D.A.P.; Ward, A.; Urbatsch, I.L.; Chang, G.; van Veen, H.W. Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. Trends Biochem. Sci., 2010, 35, 36-42.
12. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding. Science, 2009, 323, 1718-1722.
13. Ferreira, R.J.; dos Santos, D.J.V.A.; Ferreira, M.-J.U.; Guedes, R.C. Toward a Better Pharmacophore Description of PGlycoprotein Modulators, Based on Macrocyclic Diterpenes fromEuphorbiaSpecies. J. Chem. Inf. Model., 2011, 51, 1315-1324.
14. Valente, C.; Ferreira, M.J.; Abreu, P.M.; Gyemant, N.; Ugocsai, K.; Hohmann, J.; Molnar, J. Pubescenes, jatrophane diterpenes, from Euphorbia pubescens, with multidrug resistance reversing activity on mouse lymphoma cells. Planta Med., 2004, 70, 81-84.
15. Duarte, N.; Gyemant, N.; Abreu, P.M.; Molnar, J.; Ferreira, M.J. New macrocyclic lathyrane diterpenes, from Euphorbia lagascae, as inhibitors of multidrug resistance of tumour cells. Planta Med., 2006, 72, 162-168.
16. Duarte, N.; Varga, A.; Cherepnev, G.; Radics, R.; Molnar, J.; Ferreira, M.J. Apoptosis induction and modulation of P-glycoprotein mediated multidrug resistance by new macrocyclic lathyrane-type diterpenoids. Bioorg. Med. Chem., 2007, 15, 546-554.
17. Duarte, N.; Jardanhazy, A.; Molnar, J.; Hilgeroth, A.; Ferreira, M.J. Synergistic interaction between P-glycoprotein modulators and epirubicine on resistant cancer cells. Bioorg. Med. Chem., 2008, 16, 9323-9330.
18. Madureira, A.M.; Ferreira, M.J.; Gyemant, N.; Ugocsai, K.; Ascenso, J.R.; Abreu, P.M.; Hohmann, J.; Molnar, J. Rearranged jatrophane-type diterpenes from euphorbia species. Evaluation of their effects on the reversal of multidrug resistance. Planta Med., 2004, 70, 45-49.
19. Madureira, A.M.; Gyemant, N.; Ascenso, J.R.; Abreu, P.M.; Molnar, J.; Ferreira, M.J. Euphoportlandols A and B, tetracylic diterpene polyesters from Euphorbia portlandica and their anti-MDR effects in cancer cells. J. Nat. Prod., 2006, 69, 950-953.
20. Valente, C.; Pedro, M.; Ascenso, J.R.; Abreu, P.M.; Nascimento, M.S.; Ferreira, M.J. Euphopubescenol and euphopubescene, two new jatrophane polyesters, and lathyrane-type diterpenes from Euphorbia pubescens. Planta Med., 2004, 70, 244-249.
21. Duarte, N.; Lage, H.; Ferreira, M.J. Three new jatrophane polyesters and antiproliferative constituents from Euphorbia tuckeyana. Planta Med., 2008, 74, 61-68.
22. Ferreira, M.-J.U.; Madureira, A.M.; Ascenso, J.R. A Tetracyclic diterpene and triterpenes from Euphorbia segetalis. Phytochemistry, 1998, 49, 179-183.
23. Chou, T.C. Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. Cancer Res., 2010, 70, 440-446.
24. Willett, P.; Barnard, J.M.; Downs, G.M. Chemical Similarity Searching. J. Chem. Inf. Comput. Sci., 1998, 38, 983-996.
25. Tong, W.; Welsh, W.J.; Shi, L.; Fang, H.; Perkins, R. Structureactivity relationship approaches and applications. Environ. Toxicol. Chem., 2003, 22, 1680-1695.
26. Molecular Operating Environment, MOE v2010.10; Chemical Computing Group: Montreal, Canada, 2010.
27. Nissink, J.W.; Murray, C.; Hartshorn, M.; Verdonk, M.L.; Cole, J.C.; Taylor, R. A new test set for validating predictions of proteinligand interaction. Proteins, 2002,49, 457-471.
28. Cole, J.C.; Nissink, J.W.M.; Taylor, R. Protein-Ligand Docking and Virtual Screening with GOLD in Virtual Screening in Drug Discovery, editors Shoichet, B. and Alvarez, J., Taylor & Francis CRC Press, Boca Raton, Florida, USA, 2005.
29. Verdonk M.L.; Cole J.C.; Hartshorn M.J.; Murray C.W.; Taylor R. Improved protein-ligand docking using GOLD. Proteins, 2003, 52, 609-623.
30. Voigt, B.; Coburger, C.; Monár, J.; Hilgeroth, A. Structure-activity relationships of novel N-acyloxy-1,4-dihydropyridines as Pglycoprotein inhibitors. Bioorg. Med. Chem., 2007, 15, 5110-5113.
31. Wiese, M.; Pajeva, I.K. Structure-activity relationships of multidrug resistance reversers. Curr. Med. Chem., 2001, 8, 685-713.
32. Srinivas, E.; Murthy, J.N.; Rao, A.R.; Sastry, G.N. Recent advances in molecular modeling and medicinal chemistry aspects of phospho-glycoprotein. Curr. Drug Metab., 2006, 7, 205-217.
33. Engi, H.; Sakagami, H.; Kawase, M.; Parecha, A.; Manvar, D.; Kothari, H.; Adlakha, P.; Shah, A.; Motohashi, N.; Ocsovszki, I.; Molnar, J. Tumour-specific cytotoxicity and MDR-reversal activity of dihydropyridines. In Vivo, 2006, 20 (5), 637-43.
34. Suzuki, T.; Fukazawa, N.; San-nohe, K.; Sato, W.; Yano, O.; Tsuruo, T. Structure-Activity Relationship of Newly Synthesized Quinoline Derivatives for Reversal of Multidrug Resistance in Cancer. J. Med. Chem., 1997, 40, 2047-2052.
35. Mistry, P.; Stewart, A.J.; Dangerfield, W.; Okiji, S.; Liddle, C.; Bootle, D.; Plumb, J.A.; Templeton, D.; Charlton, P. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res., 2001, 61, 749-758.